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As  our knowledge  of the cellular basis  for immunity has  increased,  it has 
become apparent that the generation of effector lymphocytes does not simply 
involve reaction of precursors with antigen and subsequent differentiation to 
effector stage.  Thus  far,  in  most  models  of cellular  and  humoral  immunity 
studied, the generation of optimal immune responses requires an active collabo- 
ration  between  precursor  cells  and  ~accessory" T  cells,  whose function  is  to 
enhance or initiate some stage(s) in the subsequent differentiation of  the precur- 
sor  (1-3).  The T  cell which collaborates with B  cells in the generation of IgG 
antibody responses is termed a "helper" T cell (1). The T cell which collaborates 
with  progenitors  of cytotoxic lymphocytes in the  generation  of cell-mediated 
cytolytic responses is termed an "amplifer" T cell (2). These amplifier and helper 
T  cells  have  their  negative  counterparts  in  a  population  of T  cells  termed 
"suppressor" T  cells. It is the function of suppressor T  cells to actively prevent 
the generation of effector cells (4-6). It thus appears that the immune system 
exerts self-control through a network of positive and negative regulator T cells. 
Several cytotoxic and fluorescent probes reactive with T-cell membrane components 
have been prepared in attempts to distinguish these regulator T cells from each other and 
from the  precursors on which they act  (1,  2,  7-10).  One such probe-ftuoresceinated 
antigen-antibody complexes-defines two distinct subpopulations of  peripheral T cells, Fc 
receptor-positive (FcR+) ~  and Fc receptor-negative (FcR-) T cells (10). Functional studies 
on populations of FcR- and FcR  ÷ T cells, purified on the fluorescence-activated cell sorter 
(FACS), revealed that the FcR- T-cell subpopulation (a) was not responsive to concana- 
valin  A  (Con A)  in the  absence of FcR+  T  cells  (ll),(b)  contained the precursors of 
cytotoxic effectors of cell-mediated lympholytic (CML) responses (12), and (c) contained 
the helper T cells (10) but not the amplifier cells (12). In contrast, the FcR  + T cells (a) 
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were responsive to Con A  (11),  (b) contained the differentiated cytotoxic effector cells of 
CML responses (12), and (c) contained the amplifier T cells but not the helper T cells (10, 
12).  Both  FcR-  and  FcR  + T  cells were  capable of proliferating in  mixed  lymphocyte 
cultures upon exposure to allogeneic lymphocytes (12). 
Despite the functional distinctions between T  cells bearing or lacking the FcR, the 
functional significance of the FcR remains unclear. Dickler and Sachs (13) have reported 
evidence for a  close association of the FcR on murine B  lymphocytes and alloantigens 
controlled by loci mapping in the I  region of the H-2  complex [/-region-associated (Ia) 
antigens]. Binding of aggregated immunoglobulin to FcR of B lymphocytes is specifically 
inhibited by treatment of the cells with anti-Ia antibody. The/region of the H-2 complex 
is a  genetically complex region that controls the lymphocyte-activating determinants 
involved in mixed lymphocyte and CML reactivity, as well as the capacity to mount an 
immune response to a  variety of antigens (14). 
Recently, Ia antigens have been detected on at least a subpopulation of T cells 
(15-18).  Since the identification of the Ia antigens  expressed on subpopulations 
of T  cells would have potential significance for our understanding  of the control 
of immune  responses,  we examined  the  ability of anti-Ia antibodies to inhibit 
the  binding  of  antigen-antibody  (AgAb)  complexes  to  the  FcR  of splenic  T 
lymphocytes. In this report we present evidence that: (a) 50-70% of the FcR  ÷ T 
cells express  Ia  antigens;  (b)  only  some/-region-controlled  determinants  are 
expressed on the FcR  ÷ T  cells; and (c) subpopulations of T  cells within the FcR  ÷ 
T-cell population  may  be  distinguishable  on  the  basis  of which/-region-con- 
trolled determinant  is expressed on the cell membrane. 
Materials  and  Methods 
Methods for preparation of AgAb complexes and cell suspensions, for separation of cells on 
nylon wool, for fluorescent labeling of cells, and for analysis of cell populations on the FACS 
(FACS-II; Becton Dickinson Electronics Laboratory, Mountain View, Calif.) have been described 
in detail in a previous paper (10). Complexes of fluoresceinated egg albumin and the 7S fraction of 
anti-egg albumin from BAB/14 (Ig b) mice (F*AgAb) were used throughout this study to label the 
FcR (10). 
Mice.  Male and female  mice from  the inbred  strains of CKB,  A.TH,  A.TL, A.AL, HTI, 
AKR.M,  B10,  B10.BR,  B10.A,  B10.A(3R),  B10.A(4R),  B10.A(5R),  B10.S(gR),  B10.HTT,  and 
B10.S(7R) used in these experiments were obtained from our colonies at Stanford. The haplotype 
origin of the H-2 regions carried by each of these strains is presented in Table I. 
Antisera.  A rabbit antiserum prepared against a saline EDTA extract of mouse thymocytes 
and absorbed with mouse bone marrow cells was shown to be specific for T cells (19). Anti-Thy 1.2 
(anti-theta) was prepared by Dr. G. Michael Iverson, Stanford University, from ascites fluid elic- 
ited by intraperitoneal injection of sarcoma 180 cells into AKR mice after immunization with CBA 
thymocytes according to the method of Reif and Allen (20). Anti-Tla  serum was prepared and 
kindly provided by Dr. E. A. Boyse (21). 
Antiserum specific for mouse IgM was prepared by immunization of goats with MOPC-104E 
myeloma protein. The serum was sequentially absorbed on columns of Sepharose-4B conjugated 
with S-4  {yA) and RPC-5  (Y2~) myeloma proteins. Antisera specific for mouse ~l and ~/2a were 
prepared by immunizing goats with the Fc fragments of MOPC-21 or RPC-5, respectively. The 
anti-y1 serum was absorbed on Sepharose-4B conjugated with RPC-5 (~2a myeloma protein). The 
anti--f~ serum was sequentially absorbed on columns of Sepharose-4B conjugated with MOPC-21 
(~'1) and MPC-11  (Y~b) myetoma proteins. These class-specific anti-Ig sera were prepared by Mr. 
Derek Hewgill, Stanford University. The specificity of the above reagents for their designated 
antigens was confirmed by radioimmune assay. Fluorescein conjugates of the ammonium sul- 
fate-purified Ig of these antisera were prepared according to the method of Cebra and Goldstein 
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TABLE  I 
Haplotype Origin of H-2 Regions of Mouse Strains  Utilized 
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H-2 region* 
Strain  H-2 haplo-  I 
type  K  S  G  D 
A  B  J  E  C 
B10  b  b  b  b  b  b  b  b  b  b 
CKB, B10.BR  k  k  k  k  k  k  k  k  k  k 
B10.A  a  k  k  k  k  k  d  d  d  d 
A.AL  al  k  k  k  k  k  k  k  k  d 
B10.A(4R)  h4  k  k  b  b  b  b  b  b  b 
HTI  i  b  b  b  b  b  b  b  ?  d 
B10.A(3R)  i3  b  b  b  b  k  d  d  d  d 
B10.A(5R)  i5  b  b  b  k  k  d  d  d  d 
AKR.M  m  k  k  k  k  k  k  k  k  q 
A.TL  tl  s  k  k  k  k  k  k  k  d 
A.TH, B10.S(7R)  t2  s  s  s  s  s  s  s  s  d 
B10.HTT  t3  s  s  s  s  k  k  k  k  d 
B10.S(gR)  t4  s  s  ?  k  k  d  d  d  d 
* Adapted from Shreffler and David (14),  Shreffler et al.  (27), and Murphy et al.  (33). 
Anti-H-2 and anti-Ia sera used in this study are listed in Table II. These sera were prepared by 
immunizing with spleen and lymph node suspension (10-20 x  106 cells per mouse) on days 0, 28, 35, 
and 42. Mice were bled on days 49 and 51. Thereafter, the mice were boosted every 3rd week, and 
bled accordingly.  Pools of antisera examined were from mice that had received 5  to 10 booster 
injections.  (A.AL  x  B10)F1  anti-A.TL and (B10  ×  AKR.M)FI  anti-B10.A sera were generously 
provided by Dr. D. C. Shreffler, Washington University, St. Louis, Mo. Titers of these sera were 
determined in the dye exclusion microcytotoxicity assay using serum donor lymph node target 
cells (23). All serum preparations were deaggregated by centrifugation at 70,000 g for 1 h immedi- 
ately before use. 
Inhibition of  F*AgAb Binding by Anti-H-2 Sera.  Cell pellets containing 5 ×  106 cells each were 
resuspended in 50 gl of the test antiserum and incubated for 30 min at 37°C.  The cells were then 
pelleted through a layer of fetal calf serum, resuspended in 50 pl of F*AgAb (10), and incubated for 
30 min at 37°C.  The cells were then washed and analyzed for proportion of fluorescent cells using 
the FACS-II. 
Removal of Phagocytic Cells from Lymphocyte Suspensions.  The phagocytic cells present in 
the nylon wool-purified splenic T-cell population were removed by the carbonyl-iron technique 
described by Van Rood et al.  (24).  Briefly, the cells were suspended to  15  x  106/ml RPMI-1640 
supplemented with fetal calf serum to 5% vol/vol. Powdered iron (Fisher Scientific Co.,  Santa 
Clara,  Clalif.)  was  added  to  a  concentration  of approximately  50  mg/ml  and  the  cells  were 
incubated for 20 min at 37°C. The cell suspension was then layered over an equal volume of Ficoll- 
Paque (Pharmaeia Fine Chemicals, Inc., Piscataway, N. J.) and centrifuged at 450 g  for 45 min. 
The cells banding at the RPMI-Ficoll interface were collected with a Pasteur pipette and washed 
once before use. The extent of contamination with monocytes and/or granulocytes was determined 
cytochemically by the esterase-staining method of Yam et al.  (25), 
Results 
Inhibition  of AgAb  Complex  Binding  to  FcR + T  Cells  by  Anti-Ia  Anti- 
body.  Incubation of nylon wool-purified splenic T cells for 30 min at 37°C with 
F*AgAb complexes results in labeling of 20-40% of the T-cell population (refer- 
ence 10 and Table III). The proportion of these FcR  ÷ T cells which are labeled by 
this  technique  can  be  reduced  by 50-70%  by  incubating  the  T  cells,  before 190  THE  FC RECEPTOR ON THYMUS'DERIVED  LYMPHOCYTES 
TABLE  II 
Specificity  and Titers of Antisera 
Anti-  H-2 region incompatibility 
Strain combination  Titer* 
serum  K  A  B  J  E  C  S  G  D 
A  (B10.A(5R)  x  A.TL)F~  k  160 
anti-B10.A 
B  (A.AL  x  B10)F~  anti-  s  320 
A.TL 
C  (B10  x  AKR.M)F~  anti-  d  d  d  d  320 
B10.A 
D  A.TH anti-A.TL  k  k  k  k  k  k  k  2,560 
E  A.TL anti-A.TH  s  s  s  s  s  s  s  1,280 
F  (B10.HTT  x  A.TFR5)F,  k  k  k  160 
anti-A.TL 
G  (B10.A  x  A.TL)F,  anti-  s  s  s  160 
B10.HTT 
H  B10.A(4R) anti-B10  b  b  640 
I  B10.A(3R) anti-B10.A(SR)  k  05 
J  (B10.T(6R)  x  B10.D2)F,  k  k  k  k  1,280 
anti-B10.AQR 
K  (B10  x  HTI)FI  anti-  k  k  d  d  (d?)  120 
B10.A(SR) 
L  B10.S(7R) anti-B10.HTT  k  k  k  k  40 
* Titers listed are the reciprocal dilution of antiserum which gives 50% of maximum cytolysis of 
donor lymph node targets in the dye exclusion microcytotoxicity assay (23). 
Although not significantly cytotoxic for either T or B cells in the dye exclusion assay, antibody in 
this serum is cytotoxic for suppressor T cells as determined by functional assays (33). 
TABLE  HI 
Inhibition of AgAb Binding to T Lymphocytes by Anti-Ia Antisera 
Mouse strain  % FcR  ÷ T 
% Decrease in proportion FcR  ÷ T cells by:* 
Anti-Thy-l.2$  Anti-Tla§  Anti-Isll  Anti-Ik¶ 
A.TL  26  -  0  4  54 
A.TH  31  -  0  60  5 
B10.BR  29  0  -  5  52 
B10.S(7R)  40  -  -  63  5 
CKB  28  -  -  0  68 
* Nylon wool-purified  T cells (~95% Thy-l.2  ÷ as determined by cytotoxicity assay) were incubated 
30 min at 37°C with the designated antisera or NMS and washed through an FCS gradient. The 
cells were then labeled with F* AgAb complexes and assayed on the FACS for proportion of 
labeled cells. Fraction of Fc  + T cells and degree of inhibition were based on analysis of 10,000 
viable cells. 
$ AKR anti-C3H Thy-1, used at a  1:10 dilution, has a  100% cytotoxicity end point of >1:50 under 
conditions used for Fc inhibition. Similar results were obtained with a heterologous rabbit anti- 
thymocyte serum and rabbit anti-brain-associated T-antigen serum. 
§ Anti-Tla  1, 2,  3,  used at a  1:10 dilution in this study, has a  cytotoxicity titer of >1:2,000  for 
thymocytes. 
1I  A.TL anti-A.TH, used at a  1:20 dilution. 
¶ A.TH anti-A.TL, used at a  1:20 dilution. STOUT,  MURPHY,  McDEVITT,  AND  HERZENBERG  191 
labeling with F*AgAb, for 30 min at 37°C in a  1:20 dilution of antisera directed 
against products controlled by the I  region of the H-2 complex. This inhibition 
displayed serological specificity in that  FcR  ÷ T  cells from A.TL,  B10.BR, and 
CKB mice (I  k) were inhibited by A.TH anti-A.TL antiserum (anti-/k) but not by 
A.TL  anti-A.TH  antiserum  (anti-/'),  whereas  FcR  + T  cells  from  A.TH  and 
B10.S(7R) mice were inhibited by anti-P but not by anti-/k  (Table III). 
The inhibitory effect of these antisera cannot be ascribed to antibody against 
determinants controlled by loci mapping in the Tla region since treatment of T 
cells with antisera prepared  against Tla-region determinants  failed to inhibit 
subsequent  binding  of  F*AgAb  complexes  (Table  III).  In  addition,  strain 
B10.BR, which appears to have the same Tla region as strain  A.TH, was not 
inhibited by the A.TL anti-A.TH serum. 
Treatment ofT cells with either a T-cell specific alloantiserum (e.g., anti-Thy 
1.2) or xenoantiserum (e.g., rabbit anti-mouse brain) did not inhibit subsequent 
binding  of F*AgAb  complexes  (Table  III).  Both  of the  anti-T-cell  reagents 
displayed high  cytotoxicity titers  (>1:1,000)  against  T-cell targets.  Thus,  the 
blockade of the FcR observed with anti-Ia sera does not appear to be a general- 
ized effect of antibody reacting with T-cell membrane determinants. 
Inhibition of F*AgAb Binding to T  Cells by Anti-H-2K or Anti.H-2D Anti- 
bodies.  To  determine  whether  antisera  directed  against  de~terminants  con- 
trolled by regions of the H-2 gene complex other than the I  region could inhibit 
the binding of F*AgAb complexes to T cells, splenic T cells were incubated for 30 
min at 37°C with anti-H-2D or anti-H-2K sera and subsequently labeled with 
F*AgAb complexes. Treatment with anti.H-2K  k (serum A, Table II) reduced the 
proportion of labeled FcR  ÷ T  cells by 39% in populations of strain A  splenic T 
cells but not in populations of strain A.TL splenic T cells (Table IV). Conversely, 
treatment with anti-H-2K  8 (serum B, Table II) reduced the proportion of labeled 
FcR  + T cells in strain A.TL but not in strain A splenic T cells. Treatment with a 
1:5 dilution of anti-H-2D d (serum C, Table II) reduced the proportion of labeled 
FcR  + T cells in populations of HTI splenic T cells but not in populations of B10 
splenic T cells (Table IV). 
Comparison of Immunofluorescent Labeling Titer with FcR Inhibition Titer 
of Anti-H-2  Sera.  In light  of the ability of anti-Ia  sera to inhibit  binding of 
F*AgAb to T cells, an attempt was made to detect binding of anti-Ia antibodies 
to T  cells by indirect immunofluorescence.  Spleen cells or nylon wool-purified 
splenic T cells from A.TL mice were incubated with a 1:10 dilution of A.TH anti- 
A.TL serum for 30 min at 37°C (the same conditions which result in blockade of 
the FcR), washed, and incubated for an additional 30 min with fluoresceinated 
anti-(mouse T, and T2a)Ig. Only 41% of the spleen cells (Fig.  1 a) and 2% of the 
splenic T cells (Fig. 1 d) were labeled with a fluorescence intensity greater than 
the normal mouse serum (NMS) controls (10 units).  Similar treatment of HTI 
lymphocytes with  (B10  ×  AKR.M)F,  anti-B10.A serum  (anti-H-2D d) or A.TL 
lymphocytes with  (A.AL  ×  B10)F,  anti-A.TL  serum  (anti-H-2K  ~) followed by 
fluoresceinated anti-mouse  (T, and T2a) Ig resulted in significant labeling (>10 
U) of at least 95% of the lymphocytes (Figs.  1 b, c, e, and f). The same results 
were obtained with splenic T cells using a fluoresceinated anti  (mouse Ig)-Ig or 
anti-(mouse IgM)-Ig as the second step. The failure to detect labeling of A.TL T 192  THE  FC  RECEPTOR  ON  THYMUS-DERIVED  LYMPHOCYTES 
TABLE IV 
Inhibition of AgAb Binding to T Cells by High Concentrations of Anti-H-2 Antisera 
Mouse Strain  % Fc  ÷  T 
% Decrease in proportion of Fc  + T cells by:* 
Anti-H-2Kk$  Anti-H-2KS§  Anti-H-2D~l 
A.TL  27  0  57  - 
A  22  39  0  - 
B10  27  -  -  <5 
HTI  30  -  -  53 
* See Footnote (*), Table III. 
Serum A, Table II, used at 1:5 dilution. 
§ Serum B, Table II, used at 1:5 dilution. 
II Serum C, Table II, used at 1:5 dilution. 
cells by A.TH anti-A.TL serum was therefore not due to class restriction of the 
anti-Ia antibodies. 
During  the  course  of the  above  experiments,  it  was  noted that  the  FcR 
inhibitory activity of the  anti-H-2  sera  did  not  strictly  correlate  with  the 
cytotoxicity titers of the antisera. To determine whether the difference in FcR 
inhibition activity reflected differences in relative amount of antibody binding 
to the cell surface, the antisera were titrated simultaneously both by indirect 
immunofluorescence and by FcR inhibition. The titration by indirect immuno- 
fluorescence was run on spleen cells rather than splenic T cells since no signifi- 
cant labeling of T cells could be detected with the anti-Ia reagents (Fig. 1 d). In 
the cases  of anti-H-2D  and anti-H-2K,  the immunofluorescent titer obtained 
with spleen cells was either the same or somewhat lower than that obtained 
with nylon wool-purified splenic T cells. In all cases, splenic T cells were used for 
titration of FcR inhibition activity. The results are presented in Fig. 2. 
Dilutions of A.TH anti-A.  TL up to 1:80 consistently labeled half of the B10. BR 
spleen cells with a  fluorescence intensity greater than 10 U  and reduced the 
proportion of FcR  + T cells detected by 50%. Both the proportion of spleen cells 
labeled and the degree of FcR inhibition decreased as the antiserum was diluted 
beyond 1:80. A 1:10 dilution of A.TL anti-A.TH did not label B10.BR spleen cells 
or inhibit B10.BR T-celt FcR. A  1:5 dilution of (B10  x  AKR.M)F1 anti-B10.A 
(anti-H-2D d)  serum labeled (>10 U) 98% of HTI spleen cells and reduced the 
proportion ofFcR  ÷ T cells detected by 56%. As the antiserum was diluted beyond 
1:5, both the proportion of spleen cells labeled and the degree of FcR inhibition 
decreased (Fig. 2 b). Dilutions of (A.AL x  B10)F~ anti-A.TL serum (anti-H-2K  ~) 
up to  1:40 labeled greater than 90%  of A.TL spleen cells.  However,  the FcR 
inhibitory activity of this antiserum did not show a plateau but rather decreased 
as the antiserum was diluted, effecting only a  13% reduction in proportion of 
FcR  ÷ T cells at a  h40 dilution (Fig. 2 c). 
In none of the experiments described above was a  difference in the fluores- 
cence  distribution of F*AgAb-labeled T  cells discerned after treatment with 
inhibitory concentrations of anti-H-2D, anti-H-2K, or anti-Ia sera. For example, 
the fluorescence distributions of A.TL splenic T cells labeled with F*AgAb after 
treatment with a 1:5 dilution of NMS, A.TH anti-A.TL, or (A.AL x  B10)F1 anti- 
A.TL are shown in Fig. 3. Both antisera reduced the proportion ofT cells labeled STOUT,  MURPHY,  McDEVITT~  AND  HERZENBERG  193 
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FIG.  1.  Fluorescence distribution of spleen cells labeled with anti-H-2 antisera. Spleen 
cells (a-c) or nylon-purified splenic T cells (d-f) were incubated for 30 min at 37°C with a 
1:10 dilution of the specified reagent, washed,  and incubated for an additional 30 rain at 
37°C with a fluoresceinated rabbit anti-mouse ~t and 7~ immunoglobuIin reagent. The cells 
were then washed and analyzed using the FACS.  Distributions are based on cumulative 
analyses  of 10,000  viable cells.  (a,  d)  A.TL  splenic lymphocytes  incubated with  a  1:10 
dilution of NMS (---) or A.TH anti-A.TL (-)  (41% of spleen cells and 2% ofT cells labeled 
with a fluorescence intensity >10 U); (b, e) HTI splenic lymphocytes incubated with a  hl0 
dilution of NMS (---) or (B10 × AKR.M)F1 anti-B10.A (-)  (98% of spleen cells and 96% of T 
cells labeled with fluorescence intensity >10 U); (c, f) A.TL splenic lymphocytes incubated 
with a  1:10 dilution of NMS (---) or (A.AL ×  B10)F~ anti-A.TL (-)  (99% of spleen cells and 
97% of T cells labeled with fluorescence intensity >10 U). 
10  2o  30  40 
with a fluorescence intensity greater than 20 U by approximately 50% relative to 
NMS-treated controls. The median fluorescence intensity of the labeled popula- 
tions remained within 150-200 U  after treatment with either antisera. That is, 
the inhibition of FcR did not seem to be due to a  partial inhibition of binding 
activity of  all FcR  + T cells resulting in half of  the cells decreasing in fluorescence 
intensity below 20 U. 
Identification  of  I  Subregions  Controlling  Determinants  on  FcR ÷  T 
Cells.  Having established that  the  majority  (>50%)  of FcR+ T  cells bear I- 
region  determinants,  experiments  were  undertaken  to  map  the  locus  (loci) 
controlling  these determinants.  These studies  were conducted with several I- 
region recombinant strains  which permit mapping to different I  subregions. 194 
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FIc.  2.  Titration of anti-H-2 antisera: correlation of  fluorescent-labeling titer with inhibi- 
tion of AgAb binding to T cells. Spleen cells ( - ) or nylon wool-purified splenic T cells (---) 
were incubated for 30 min at 37°C with the specified antisera.  The cells were washed and 
subsequently incubated for 30 min at 37°C with either fluoresceinated rabbit anti-mouse ~ 
and 72 immunoglobulin ( - ) or F*AgAb complexes (---). The cells were washed and assayed 
on the  FACS to determine  the proportion of spleen cells labeled (-) or the degree of 
inhibition of AgAb binding to the splenic T cells (---) relative to a NMS control. Values are 
based on cumulative  analysis  of 10,000 viable cells. (a) B10.BR spleen or splenic T cells 
treated  with anit-1  k (A.TH anti-A.TL); (b) HTI spleen or splenic T cells treated with anti- 
H-2D '~ [(B10 x AKR.M)F1 anti-B10.A]; (c) A.TL spleen or splenic T cells treated  with an 
anti-H-2K  s [(A.AL x B10)F~ anti-A.TL]. 
The data obtained from studies on FcR inhibitory activity of anti-Ia serum on 
splenic  T  cells from B10.HTT mice demonstrate that  at least  two loci control 
determinants  present  on  FcR  +  T  cells  (Table  V).  The  crossover  in  strain 
B10.HTT occurred between the I-J and I-E subregions, such that it carries the I- 
A, I-B, and I-J subregions derived from the H-2  ~ haplotype and the I-E and I-C 
subregions derived from the H-2  k haplotype. Treatment of B10.HTT splenic T 
cells with A.TL anti-A.TH (anti-P) serum resulted in a 50% reduction in FcR  + T 
cells, whereas treatment with A.TH anti-A.TL (anti-/k) serum resulted in a 30% 
reduction in FcR  ÷ T cells (Table V).  Similar results were obtained using (A.TL 
x  B10.A)F1  anti-B10.HTT  and  B10.S(7R)  anti-B10.HTT  (Table  V).  It  thus 
appears that loci mapping on opposite sides of the crossover in B10.HTT control 
determinants found on FcR  ÷ T  cells. 
The  FcR inhibition  data  obtained  with  strains  B10.A(4R)  and  B10  demon- 
strate that one of the loci discussed above maps in the/-A subregion. These two 
strains differ in the H-2K and I-A  subregions. Serum produced by immunizing 
B10.A(4R) recipients with B10 donor tissue contains antibody against determi- 
nants  controlled  by both  regions.  After  absorption  with  EL-4 tumor  cells  to 
remove H-2K antibody, this serum inhibited binding of F*AgAb complexes to 
B10 FcR  ÷ T  cells  (Table V).  Similar results were obtained with a  (B10.HTT  x 
A.TFR5)F, anti-A.TL serum,  which contains antibody reactive with/-A deter- 
minants carried by strain B10.A(4R) (Table V). 
Determinants controlled by the I-J subregion do not appear to be present on 
FcR  ÷ T  cells,  since  a  B10.A(3R)  anti-B10.A(5R)  serum,  which  was  known to 
contain antibody against  determinants  controlled by the I-J  subregion of the 
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FIG. 3.  Fluorescence distribution of  splenic T  cells labeled with F*AgAb  complexes  after 
treatment with anti-H-2 antisera, Nylon  wool-purified A.TL  splenic T cells were incubated 
with a  1:5 dilution of NMS  (-) or specific anti-H-2 sera (---)  for 30 rain at 37°C. The cells 
were subsequently washed  and incubated for 30 min at 37°C with F* AgAb  complexes. The 
cells were  washed  and  analyzed  on the FACS,  Distributions  are based on  cumulative 
analysis of  10,000 viable cells  of  which 27% were FcR +. (a) A.TL  splenic T cells  treated with 
NMS  (-) or with A.TH  anti-A.TL  (---);  (b) A.TL  splenic T cells treated with NMS  (-) or 
(A.AL  x  B10)F~ anti-A.TL  (---).  Both antisera reduced the frequency of AgAb-binding  T 
cells by approximately 50%  relative to NMS-treated  cells. 
TABLE V 
Inhibition of AgAb Binding to T Cells by Antisera Specific for I-Region-Controlled 
Determinants 
Mouse strain 
I-Region  % Decrease  in proportion FcR+ T  cells  * after treatment  with antisera specific for: 
% FcR  ~  ,  ............................... 
A  B  J  E  C  Ik~  I'§  A'B'J'[t  AkBkJk¶  AkBWJ~'Ek**  A~,$:~  jK§ §  JkEkC~  [ [[  E~,Ck¶¶ 
B10.BR  k  k  k  k  k  27  52  5  9  44  64  .... 
B10 S(7R)  s  s  s  s  s  24  5  63  41  ....  4  7 
BI0  b  b  b  b  b  22  -  7  9  35  3  0  4 
BI0.HTT  s  s  s  k  k  26  31  52  40  0  .....  30 
B10.A(3R)  b  b  b  k  d  24  3  9  -  4  40  5 
BI0.A(4R)  k  b  b  b  b  21  -  30  -  0  -  0  - 
B10.A(5R)  b  b  k  k  d  33  -  0  0  -  2  37  3 
S10~S{gR)  s  s  k  k  d  20  31  ....  47  0 
*  See  footnote  (*),  Table  IIL 
?  Serum D,  Table II,  used  at 1:20  dilution. 
§  Serum E, Table II,  used  at  1:20  dilution. 
I[  Serum G, Table II,  used  at 1:10  dilution. 
¶ Serum F,  Table  II,  used at 1:5  dilution. 
**  Serum J,  Table If,  used  at 1:10  dilution. 
*~  Serum H, Table II,  used at  1:5  dilution  after  absorption  with  EL-4, 
§§  Serum I,  Table  If,  used  at 1:5  dilution. 
II  ~  Serum K,  Table If,  used  at  1:5  dilution.  Similar  results  obtained  with 1:20  dilution. 
¶¶  Serum L,  Table IL used  at 1:5  dilution.  Similar  results  obtained  with 1:20  dilution. 196  THE  FC  RECEPTOR  ON THYMUS-DERIVED LYMPHOCYTES 
H-2  ~" haplotype, failed to inhibit the binding of F*AgAb complexes to B10.A(5R) 
FcR  + T cells (Table V). This conclusion was supported by the failure of (B10.HTT x 
A.TFR5)F,  anti-A.TL  serum  to  inhibit  binding  of  F*AgAb  complexes  to 
B10.A(5R) FcR  ÷ T cells. 
A second locus controlling determinants on FcR  + T cells appears to map to the 
right of the/-E subregion. Determinants controlled by the I-E subregion were 
initially detected by the  cytotoxic reactivity of a  (C3H.Q  x  B10.D2)F,  anti- 
B10.AQR serum with B10.A(5R) spleen cell targets (26-27). A serum produced in 
a  similar  strain  combination  [(B10.T(6R)  x  B10.D2)F,  anti-B10.AQR]  gives 
negligible inhibition of F*AgAb binding to B10.A(5R) FcR  ÷ T cells (Table V). In 
addition, a  B10.S(7R) anti-B10.HTT serum, which contains antibody against/- 
E-subregion-controlled determinants, failed to inhibit binding of F*AgAb com- 
plexes to FcR  ÷ T cells from strains sharing the same I-E subregion [B10.A(5R), 
B10.A(3R), and B10. S(9R)]. These data suggest that determinants controlled by 
the I-E subregion are not present on FcR  ÷ T cells. 
In contrast to its  effect on  FcR  ÷ T  cells from strains  3R,  5R,  and  9R,  the 
B10.S(7R) anti-B10.HTT serum significantly inhibits the binding of F*AgAb 
complexes to B10.HTT FcR  ÷ T cells (Table V). This inhibition must be due to 
determinants controlled by a  locus mapping in the PC, S, or G  regions. Data 
obtained with a  (B10 x  HTI)F, anti-B10.A(5R) serum would also be consistent 
with this interpretation (Table V). Experiments are in progress to definitively 
map this locus. 
Evidence for Distinct FcR + T-Celt Subpopulations Expressing Determinants 
Controlled by Different I Subregions.  The experiments presented above dem- 
onstrated that at least two loci mapping on opposite sides of the crossover in 
B10.HTT mice control determinants that are expressed on FcR  ÷ T  cells. Anti- 
sera  reactive  with  these  two  sets  of determinants  were  titrated in  the  FcR 
inhibition assay individually or in combination to determine whether both sets 
of determinants were present on the same subpopulation of FcR  ÷ T cells or on 
different subpopulations of FcR  ÷ T cells. Treatment of B10.HTT splenic T cells 
with 1:40 dilution of A.TH anti-A.TL serum resulted in a 30% reduction in the 
proportion of FcR  ÷ T  cells labeled, whereas treatment with a  1:40 dilution of 
A.TL anti-A.TH serum resulted in a 50% reduction in the proportion of FcR  ÷ T 
cells  (Fig.  4).  Increasing the concentration of either serum did not result in 
increases in FcR inhibition. Treatment of the B10.HTT splenic T cells with both 
antisera resulted in a  70% reduction in FcR  ÷ T cells (Fig. 4). In several repeti- 
tions of this experiment, treatment with a  1:10 to 1:40 dilution of A.TL anti- 
A.TH serum resulted in a  30-50% reduction in FcR  ÷ T cells, treatment with a 
1:10 to  1:40 dilution of A.TH anti-A.TL resulted in a  20-30%  inhibition,  and 
treatment with  a  1:10 to  h40  dilution of both  antisera resulted in  a  50-70% 
reduction in  FcR  + T  cells.  The partially additive effect of these two antisera 
indicates that some FcR  ÷ T cells express one, but not both, of the two sets of Ia 
determinants. 
In all of the above experiments, contamination of the splenic T-cell prepara- 
tion with "non-T" cells was less than 5% as determined by immunofluorescent 
labeling  with  anti-Thy  1.2,  heterologous anti-T  antisera,  and/or  anti-Ig.  To 
exclude the possibility that a  macrophage contaminant might represent one of STOUT,  MURPHY,  MCDEVITT~  AND  HERZENBERG 
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FIG. 4.  Inhibition  of  AgAb binding to BI0.HTT splenic  T cells  by anti-/-region  antisera. 
Nylon wool-purified  B10.HTT splenic  T cells  were incubated for  30  rain  at  37°C with  anti-/k 
(A.TH anti-A.TL), anti-P (A.TL anti-A.TH), or both.  The cells  were w~shed and subse- 
quently incubated for  30 rain  at 37°C with F*AgAb complexes. The cells  were washed and 
assayed on the FACS for  proportion of  labeled cells.  Degree of  inhibition  relative  to  NMS/ 
treated controls  is  based on cumulative analysis of  10,000  viable  cells. 
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TABLE  VI 
I-Subregion-Specific Inhibition of AgAb Binding to Macrophage- 
Depleted BIO.HTT Splenic T Cells 
% 
Cell population  % Esterase ÷  FcR+ 
% Decrease in propor- 
tion of Fc  + cells* by: 
Anti-Ik$  Anti-P§ 
Nylon T  3  23  25  48 
Macrophage-depleted] t ny-  <1  20  40  40 
ton T 
* See footnote (*), Table III. 
$ A.TH anti-A.TL, 1:20 dilution. 
§ A.TL anti-A.TH, 1:20 dilution. 
II After nylon wool purification, the splenic T cells were incubated with iron 
filings for 45 min at  37°C, layered over a  cusion of Ficoll-Hypaque, and 
centrifuged for 1 h.  The cells  banding above the Ficoll-Hypaque were re- 
covered and used as the macrophage-depleted T cells. 
the populations of cells inhibited by one of the antisera,  B10. HTT splenic T cells 
(3%  esterase  positive)  were  depleted  of phagocytic  cells  by the  carbonyl-iron 
technique.  The T-cell population treated in this manner  contained less than  1% 
esterase-positive  cells  (Table  VI).  Treatment  of these  macrophage-depleted 
B10.HTT  splenic  T  cells  with  either  A.TH  anti-A.TL  or A.TL  anti-A.TH  re- 198  THE  FC  RECEPTOR  ON  THYMUS'DERIVED  LYMPHOCYTES 
suited in a 40% reduction in the proportion of FcR  ÷ cells subsequently labeled, 
suggesting that the FcR  + cells inhibited by either antisera were T cells. 
Discussion 
It has previously been demonstrated in several laboratories that treatment of 
B lymphocytes with anti-Ia  sera markedly inhibits the binding of AgAb com- 
plexes to the B-cell FcR (reviewed in reference 28).  In the present report,  we 
have demonstrated that treatment of splenic T cells with anti-Ia  sera inhibits 
the binding of AgAb complexes to the majority of FcR  ÷ T cells. 
Several potential mechanisms have been proposed to explain the inhibition of 
FcR by anti-Ia  antibodies:  (a)  the antibodies,  once bound to their  membrane 
antigens, form AgAb complexes and bind to the FcR via their Fc portions (29); 
(b) antibodies that bind to cell membrane determinants sterically obstruct the 
FcR (29); and (c) the Ia antigens are physically associated with, or identical to, 
the FcR in the cell membrane (13). The first possibility seems unlikely in view of 
the observation that Fab fragments of anti-Ia antibodies inhibit the FcR, as well 
as intact molecules (13, 28, 29).  The second hypothesis predicts that any anti- 
body which binds to membrane determinants, regardless of whether or not those 
determinants  are  associated with  the  FcR,  will  inhibit  the  binding  of AgAb 
complexes to the FcR. This hypothesis was based on the observation that  any 
antibody which binds to the B-cell membrane-including  anti-Ig,  anti-Ly-4.2, 
anti-H-2D,  and  anti-H-2K-will inhibit  rosetting  of antibody-coated erythro- 
cytes (29).  However, it  is possible that  the rosette  assay may be excessively 
sensitive to this type of steric inhibition  (28,  30).  Dickler and Sachs  (13),  who 
used aggregated Ig to detect the FcR, have found that inhibition of the B-cell 
FcR, is not effected by anti-Ig, anti-H-2K, or anti-H-2D. In the case of the T-cell 
FcR, we have found that  anti-Thy  1.2 or heterologous anti-T-cell  sera,  which 
densely label the T-cell membrane,  do not produce any detectable inhibition of 
binding of F*AgAb complexes to the T-cell FcR (Table III). 
Contrary to the findings of Dickler and Sachs (13) that anti-H-2D or anti-H- 
2K antibodies did not inhibit the B-cell FcR, we have observed that both anti- 
H-2D  and  anti-H-2K  sera  inhibit,  to  some degree,  the  T-cell  FcR.  This  FcR 
inhibitory effect of the anti-H-2D and anti.H-2K sera, in contrast to that of the 
anti-Ia sera, was only observed at relatively high serum concentrations. In the 
case of the  (A.AL  x  B10)F1  anti-A.TL  serum,  the  FcR inhibition  titer  was 
markedly lower than the fluorescence-labeling titer (Fig. 2 c). It is thus possible 
that the observed inhibition was due to steric effects resulting from saturation of 
the  membrane  with  anti-H-2D  or  antioH-2K  antibodies.  Alternatively,  the 
inhibition  may have been due to the presence of antibodies against currently 
unknown determinants controlled by loci mapping close to the D or K ends of the 
H-2 gene complex. 
The  data  presented  in  this  report  neither  proves nor  disproves a  physical 
association  between  the  T-cell  FcR and  Ia  antigens.  The  arguments  for  or 
against  such an association have been amply discussed elsewhere (13,  28,  29) 
and  will not be elaborated here.  One point of agreement,  however, is that  in 
order for an  antibody to interfere  with  the  FcR on the  cell  membrane,  that 
antibody must first bind to its antigen  (28, 29). Therefore, the ability of anti-Ia STOUT,  MURPHY,  McDEVITT,  AND  HERZENBERG  199 
antibodies to block the T-cell FcR demonstrates the existence of Ia antigens on 
peripheral  FcR  + T lymphocytes. 
Initial serological studies with peripheral T lymphocytes (16, 31, 32),  Con A- 
stimulated  blasts  (18),  and  cortisone-resistant  thymocytes  (15,  17)  suggested 
that at least some thymus-derived lymphocytes express/-region determinants. 
Data presented in this report show that determinants controlled by loci mapping 
in the I-A and I-C, S, or G regions are present on the population of peripheral T 
lymphocytes which bear an Fc receptor.  Whether these determinants  are con- 
trolled  by the Ia-1  and  Ia-3  loci,  which  mark  the  I-A  and I-C  subregions, 
respectively,  and  whether  they are  shared  with  B  lymphocytes has not been 
resolved. In contrast, determinants controlled by loci mapping in the I-J and I-E 
subregions  are  not detectable on the  FcR  + T-cell  population,  which  indicates 
either that antibodies against these determinants  do not interfere with the T- 
cell FcR or that these determinants  are not expressed on the FcR  + T cells. 
Recently,  distinct  functional  subpopulations  of T  lymphocytes  have  been 
shown  to  carry  determinants  controlled  by separate Ia  loci.  The Ia-4  locus, 
which marks the I-J subregion, controls determinants present on allotype (Ig- 
lb) suppressor T  lymphocytes but not on helper T  or B  lymphocytes (33).  The 
same locus, or other loci mapping in I-J, control determinants found on carrier 
(keyhole limpet hemocyanin)-specific suppressor T cells (34). 
There is currently conflicting evidence regarding expression of I-region loci in 
helper T lymphocytes. Hiimmerling (35) and Press [reviewed by McDevitt et al. 
(36)]  have  not been  able to detect Ia  determinants  on this  subpopulation.  In 
contrast,  Okumura et al. (37) have reported that determinants controlled by an 
/-region  locus  (subregion unknown)  distinct  from Ia-4  distinguishes  helper T 
cells from suppressor T cells. The determinants found on helper T cells appear to 
be distinct  from those found on FcR  + T  cells since (a)  helper  T  cells are  not 
included in the FcR  ÷ T-cell  population  (10),  and (b) sera containing  antibody 
against/-A-subregion-controlled  determinants  inhibit  binding  of AgAb  com- 
plexes to FcR  + T cells but do not kill helper T cells (37). Taken together, these 
data  suggest  that  different  /-region  loci  are  selectively  expressed  in  three 
distinct T-cell subpopulations: suppressor T cells, helper T cells, and Fc receptor- 
bearing T cells. 
Evidence for phenotypic and functional heterogeneity within the FcR  ÷ T-cell 
population has been accumulating  in other systems.  The FcR  ÷ T  cells appear 
heterogeneous with respect to their expression of the Ly determinants  defined 
by Shiku et al. (8). Phenotypic analysis of FcR  + T cells isolated from spleens and 
lymph nodes of normal mice suggest that all three Ly phenotypes -  Ly-l,2,3, Ly- 
1, and Ly-2, 3-exist within the FcR  ÷ T-cell population. 2 The FcR  ÷ T cells also 
appear to be phenotypically heterogeneous with respect to their expression of Ia 
determinants.  Only 50-70% of the splenic FcR  ÷ T cells are inhibitable by anti-Ia 
sera.  Similar results have been recently obtained using thymocytes (15).  It is 
unlikely  that  this  failure  to  obtain  100% inhibition  by anti-Ia  represents  a 
limitation  of the  assay system since  (a)  90%  inhibition  of B-cell  FcR can  be 
2 Stout, R. D., H. Cantor, F-W. Shen, E. A. Boyse, and L. A. Herzenberg. 1976. The Fc Receptor 
on thymus-derived lymphocytes. V. Distinct subsets within FcR- and FcR+ T cells defined by their 
expression of Thy 1 and Ly antigens. Manuscription in preparation. 200  THE  Fc  RECEPTOR  ON  THYMUS-DERIVED  LYMPHOCYTES 
obtained by anti-Ia treatment (13, 29), and {b) the degree of  inhibition ofFcR  + T 
cells plateaued at 50-70%  over a  40-fold  dilution range of the anti-Ia sera.  It 
therefore appears that 30% of the FcR  ÷ T cells do not express Ia determinants 
detectable  by  the  FcR  inhibition  assay.  [Dickler  et  al.  (38) have  reported 
inhibition of FcR activity with antisera directed against determinants controlled 
by loci  mapping outside of the H-2  gene complex.  It would be of interest to 
determine if  these determinants are expressed on FcR  + T cells, specifically  those 
that are not inhibited by anti-Ia sera.] 
Phenotypic heterogeneity with respect to expression of Ia determinants may 
also exist within the population of FcR  ÷ T cells which are inhibited by anti-Ia 
sera.  Treatment  of B10.HTT  splenic  T  cells  with  antisera  directed  against 
determinants controlled by loci mapping to the right of I-J resulted in 30-40% 
inhibition of AgAb complex binding over a 40-fold dilution range of antiserum, 
whereas treatment with antiserum directed against determinants controlled by 
loci mapping to the left of I-E resulted in 40-50% inhibition (Fig. 4 and Table V). 
Treatment with both antisera resulted in 50-70% inhibition. This additive effect 
of  the antisera, taken together with the data presented in Table V and discussed 
above, suggests the existence of subsets of FcR  + T cells which exclusively ex- 
press/-A-controlled determinants and/or FcR  + T cells which exclusively express 
I-C-, S-, or G-controlled determinants. How much overlap might exist between 
these two subpopulations is not known. 
We  have  previously  demonstrated that  the  FcR  +  T-cell  subpopulation  is 
functionally heterogeneous (10-12).  It is  considered possible that these func- 
tional subsets may be distinguishable by their selective expression of  Ia determi- 
nants since (a) other functional subsets of  T cells- e.g., helper and suppressor T 
cells-have been distinguished on the basis of  selective expression of  Ia determi- 
nants (33, 34, 37), (b) selective expression of  Ia determinants on FcR  ÷ T cells has 
been demonstrated (vide  supra),  and (c)  functional activities attributable to 
FcR  + T cells have been shown to be inhibitable by treatment of the T cells with 
anti-Ia sera plus complement (33, 39). 
For example, we have demonstrated that FcR  + T cells are responsive to Con 
A, whereas FcR- T cells, in the absence of FcR÷ T cells, do not respond to Con A 
(11). FcR- T cells do, however, seem to respond to Con A in the presence ofFcR  ÷ 
T  cells.  On the basis of responses  of mixtures of FcR  ÷ and FcR- T  cells,  we 
postulated that the  Con  A-stimulated FcR  ÷ T  cells are capable  of either (a) 
initiating or amplifying a mitotic response to Con A in the FcR- T-cell popula- 
tion, or (b) ~'recruiting" FcR- T cells into a mitotic response, e.g., by elaboration 
of a  mitogenic factor (11). Recently, Niederhuber et al.  (40) have reported that 
Con A  responsiveness of T  cells can be abrogated by treatment with anti-Ia 
serum plus complement before exposure to Con A. It would thus appear that the 
Con A-responsive FcR  + T cell falls into the FcR  ÷ T-cell subset whose FcR are 
sensitive to inhibition by anti-Ia sera. 
Similarly, it has been demonstrated that the FcR+ T-cell population contains 
the amplifier T cell (Ly-1, FcR  +) and the differentiated cytotoxic effector T cell 
(Ly-2, FcR  ÷) involved in CML reactions (12). It has been recently reported that 
treatment of the responder T  cells with anti-Ia plus complement reduces the 
generation of cytotoxic lymphocytes (39). However, it was not clear whether the STOUT,  MURPHY,  McDEVITT,  AND  HERZENBERG  201 
Ia  determinants  were  expressed  on  amplifier T  cells,  the  precursor  of the 
cytotoxic T cell, or both. Previous studies have not indicated the presence of Ia 
determinants on  either precursors  of cytotoxic lymphocytes or  the  cytotoxic 
lymphocyte  itself (32). Whether the FcR  + amplifier or cytotoxic T cells express Ia 
determinants  and,  if so,  which /-region  loci  control  these  determinants  is 
presently under investigation. 
Summary 
Treatment  of splenic  T  lymphocytes with  anti-Ia  antiserum  inhibits  the 
binding of antigen-antibody (AgAb)  complexes to the majority (>50%)  of Fc 
receptor-positive (FcR  +) T cells. A similar inhibition was observed with anti-H- 
2D  and  anti-H.2K sera but not with anti-Thy 1.2.  Despite the presence of Ia 
determinants on peripheral T  cells, as established by the inhibition of AgAb 
binding, Ia could not be detected on peripheral T cells by immunofluorescence 
assays. 
Data obtained with the AgAb-binding inhibition assay indicate that determi- 
nants controlled by loci mapping in the I-A and I-C, S, or G regions are present 
on the FcR  + T cells. Evidence is presented that subpopulations of T cells within 
the  FcR  ÷ T-cell  population may be  distinguishable on the  basis  of which I- 
region-controlled determinant is expressed. The data are discussed in terms of 
phenotypic and functional heterogeneity of T lymphocytes. 
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